Advertisement
Advertisement
U.S. Markets open in 2 hrs 4 mins
Advertisement
Advertisement
Advertisement
Advertisement

Avinger, Inc. (AVGR)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.7186+0.0085 (+1.20%)
At close: 4:00PM EDT
0.7350 +0.02 (+2.28%)
Pre-Market: 07:05AM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.7101
Open0.7200
Bid0.0000 x 900
Ask0.0000 x 1000
Day's Range0.7042 - 0.7294
52 Week Range0.2140 - 2.6700
Volume966,176
Avg. Volume890,895
Market Cap68.52M
Beta (5Y Monthly)1.71
PE Ratio (TTM)N/A
EPS (TTM)-0.3240
Earnings DateJul 28, 2021 - Aug 02, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.50
  • Benzinga

    Avinger's Shares Move Higher As Pantheris Shows Safety, Efficacy For In-Stent Restenosis

    Avinger Inc (NASDAQ: AVGR) has announced that clinical data from the INSIGHT study were presented at the VIVA (Vascular InterVentional Advances) conference. The INSIGHT trial was designed to evaluate the safety and effectiveness of Avinger's Pantheris image-guided atherectomy system for in-stent restenosis (ISR) in lower extremity arteries. Related: Avinger Files US Application For New Pantheris In-Stent Restenosis Indication. Key outcomes presented from the trial include: 82% luminal gain (incr

  • ACCESSWIRE

    Ground-Breaking Clinical Data from INSIGHT Trial Presented at VIVA

    Study Outcomes Demonstrate Safety and Efficacy of Pantheris for Treatment of In-Stent RestenosisREDWOOD CITY, CA / ACCESSWIRE / October 7, 2021 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced that clinical data from the INSIGHT study were presented during the Late-Breaking Clinical Trials session at the VIVA (Vascu

  • ACCESSWIRE

    Avinger To Present at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15

    REDWOOD CITY, CA / ACCESSWIRE / September 8, 2021 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced that its management will participate in investor meetings September 13-15, 2021 as part of the H.

Advertisement
Advertisement